Nektar, stung by new investor lawsuit over IL-2 drug, secures $150M for Keytruda combo pivotal trial
Nektar Therapeutics’ IL-2 drug hasn’t always lived up to expectations in the four and a half years since it scored a prominent ally in Bristol …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
